measurements were quantified as previously described in detail (68).
Introduction
Mitofusin-2 (MFN2) is a mitochondrial GTPase that plays a pivotal role in mitochondrial dynamics, including regulation of mitochondrial fusion, transport, mitophagy, mtDNA stability, and mitochondria-ER interactions (1) (2) (3) (4) (5) . Given the high-energy demand of neurons coupled with their unique cellular architecture (axons, dendrites), proper mitochondrial dynamics are required to provide energy when and where it is needed (6, 7) . Disruption of mitochondrial dynamics has been linked to a diverse spectrum of neurological conditions, including Parkinson's disease and Alzheimer's disease (7, 8) . In some of these cases, alterations in MFN2 function and mitochondrial dynamics may play a role in disease pathogenesis. For example, in Parkinson's disease, MFN2 plays a key role in PINK1-Parkin-mediated mitophagy (5, 9) and Mfn2 knockout in dopaminergic neurons impairs Parkin localization to mitochondria, leading to severe axonal loss (10) . In Alzheimer's disease, MFN2 protein levels are decreased in both patient brain tissue and transgenic mouse models, and amyloid-β-mediated disruption of mitochondrial dynamics may contribute to the toxicity of amyloid-β (11, 12) . However, while MFN2 function has been implicated in a variety of diseases, MFN2 mutations are only directly responsible for Charcot-Marie-Tooth disease type 2A (CMT2A) (13) .
CMT is one of the most common inherited neurological disorders, and MFN2 mutations are the most frequently identified cause of axonal CMT (CMT type 2). Most cases are de novo dominant or show dominant inheritance, although recessive cases have also been reported (13, 14) . The typical clinical features of CMT2A include early onset and progressive distal weakness, muscle atrophy, and sensory loss from degeneration of long peripheral axons (15) . However, CMT2A represents a broader spectrum of neurologic disease, including optic atrophy (16) , spastic paraparesis (17) , hearing loss (18) , developmental delay (19) , and brain white matter changes (18) . This indicates that, while long peripheral axons are most sensitive to MFN2 mutations, CMT2A is actually a broader disorder of primarily the central and peripheral nervous systems that can rarely also involve muscle or fat tissue (20, 21) .
As MFN2 is ubiquitously expressed and loss of function is detrimental to many tissues (1, 4, 10, (22) (23) (24) (25) , it remains unclear what causes MFN2 mutations to preferentially affect the nervous system, although key candidates include the low level of MFN1 expression relative to other tissues and the unique energy demands of axons, which require proper mitochondrial transport and localization (6, 7, 26) . MFN1 can compensate for loss of MFN2 and protect the mitochondrial fusion and transport defects caused by MFN2 mutants in vitro (26, 27) . However, it has been challenging to investigate the role of the MFN1/MFN2 ratio in vivo, as existing CMT2A transgenic mouse models have either a static congenital phenotype (28) or a mild late-onset phenotype (29) (30) (31) , with none recapitulating the severity or broader spectrum of neurological damage observed in CMT2A patients.
To better understand the role of MFN2 mutation in vivo, we generated transgenic mice expressing either WT or point mutant (MFN2 R94Q ) under the neuronal-specific Thy1.2 promoter. Thy1. 2 
-MFN2
R94Q transgenic mice recapitulated a range
Mitofusin-2 (MFN2) is a mitochondrial outer-membrane protein that plays a pivotal role in mitochondrial dynamics in most tissues, yet mutations in MFN2, which cause Charcot-Marie-Tooth disease type 2A (CMT2A), primarily affect the nervous system. We generated a transgenic mouse model of CMT2A that developed severe early onset vision loss and neurological deficits, axonal degeneration without cell body loss, and cytoplasmic and axonal accumulations of fragmented mitochondria. While mitochondrial aggregates were labeled for mitophagy, mutant MFN2 did not inhibit Parkin-mediated degradation, but instead had a dominant negative effect on mitochondrial fusion only when MFN1 was at low levels, as occurs in neurons. Finally, using a transgenic approach, we found that augmenting the level of MFN1 in the nervous system in vivo rescued all phenotypes in mutant MFN2
R94Q
-expressing mice. These data demonstrate that the MFN1/MFN2 ratio is a key determinant of tissue specificity in CMT2A and indicate that augmentation of MFN1 in the nervous system is a viable therapeutic strategy for the disease.
Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model WT (n = 5), MFN2 R94Q (n = 6) (3-month-old mice). (I) Rotarod testing. nTg (n = 5), MFN2 WT (n = 5), MFN2 R94Q (n = 6). (J) Grip-strength testing (forelimbs). nTg (n = 8-11), MFN2 WT (n = 5), MFN2 R94Q (n = 6). (K) Visual acuity measured by OKR. nTg (n = 6), MFN2
WT (n = 3), MFN2 R94Q (n = 7). In G-K, data are represented as mean ± SEM. Two-way ANOVA with Tukey's test was used for multiple comparison. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. R94Q mice showed stunted growth ( Figure 1 , B and E) and died prematurely from failure to thrive (25% died by 15 months of age; Figure 1F ). By 3 months of age, MFN2 R94Q mice showed a wobbling gait defect and occasionally dragged their hind limbs (Supplemental Video 1). By 10 months, MFN2 R94Q mice had severe uncoordinated movements and hind limb paw clasping (Supplemental Figure 3) , a neurologic finding commonly seen in mouse models of neurodegeneration (36) .
No change in total activity was present on open-field testing; however, rearing activity (standing up on the side of the cage) was reduced in MFN2 R94Q mice ( Figure 1 , G and H). On rotarod testing, MFN2 R94Q mice fell off significantly earlier than either MFN2 WT or nontransgenic mice and did not improve over time ( Figure 1I ). MFN2 R94Q mice also showed weaker grip strength than MFN2 WT or nontransgenic control mice ( Figure 1J ). Given that some CMT2A patients have optic atrophy and vision loss, we examined response to visual stimulation on optokinetic response (OKR) testing and found that MFN2 R94Q mice also had severe vision loss ( Figure 1K ). While MFN2 R94Q mice declined in terms of overt coordination and clasping, most of these phenotypes were static and early onset. The early onset and sensorimotor deficits with vision loss in MFN2 R94Q mice are consistent with the broader spectrum of neurologic dysfunction seen in the more severe CMT2A patients, including those carrying the R94Q mutation who typically have onset in the first decade of life.
Axon atrophy and degeneration without neuronal cell body loss in MFN2 R94Q mice. CMT2A patients have a spectrum of neurologic dysfunction, including optic atrophy (16) , spinal cord involvement with spastic paraparesis (17) , and brain involvement with developmental delay (18, 19) . We therefore examined MFN2 R94Q mice broadly for neuronal and axonal pathology in the central and peripheral nervous system. At 5 months of age, we observed diffuse axon degeneration on Fluoro-Jade staining in white matter tracts of the brain, including pyramidal tracts of the medulla and the lumbar spinal cord ( Figure  2A) . Surprisingly, in the distal tibial nerve, which typically shows severe axon loss in CMT2A patients, axons were smaller in caliber, but were normal in number, without degenerating profiles such as those seen in the spinal cord or brain ( Figure 2 , B and C). Similar axonal atrophy without degeneration has been observed in other mouse models of axonal CMT (29, 37, 38) , possibly due to shorter length, species differences, or lower promoter expression in peripheral neurons. In whole mounted retinas, neurofilament staining showed beaded, swollen, and degenerating axons with atrophic retinal ganglion cells (RGCs) in MFN2 R94Q mice ( Figure 2D ). In optic nerves, SMI32 staining showed significant neurofilament loss and axonal spheroids in MFN2 R94Q mice ( Figure 2E and Supplemental Figure 4A ), presumably explaining the vision loss in these animals. Interestingly, axon degeneration occurred in the absence of cell body loss throughout the nervous system, as no quantitative neuronal loss was observed in the retina, brain, or spinal cord, including motor cortex, sensory cortex, of neurologic features seen in CMT2A patients, including severe early onset sensorimotor deficits, vision loss, altered mitochondrial dynamics, and widespread axonal degeneration. Increased expression of MFN1 in the nervous system rescued MFN2 R94Q mutant phenotypes, demonstrating that the balance of MFN isoforms is likely the key contributor to nervous system selectivity in CMT2A and providing proof of concept in vivo that augmenting MFN1 levels is a potential therapeutic strategy for the disease. Figure 1, A and  B) . We chose this promoter because it drives expression postnatally in most neurons, including projection neurons of the brain and spinal cord, which are most severely affected in CMT2A and show cell-autonomous defects from mutant MFN2 expression in vitro (32) . We selected the R94Q variant, as dominant point mutations in this and neighboring residues in the GTPase domain have been reported across numerous ethnic backgrounds with a consistently severe phenotype with onset in the first decade that may include optic atrophy, spasticity, developmental delay, and brain white matter abnormalities (13, 17, (33) (34) (35) and as previous in vitro studies demonstrated a dominant negative effect on mitochondrial fusion and transport (3, 26, 27, 32) . We focused our analysis on 2 transgenic lines that showed comparable expression of either MFN2
Results

Generation
WT (WT-47 line) or MFN2 R94Q (R94Q-44 line). Because the Thy1. R94Q transgene was integrated into the Y chromosome in the R94Q-44 line, only male mice were analyzed for both lines. A second mutant transgenic line (R94Q-62) was also generated with a similar phenotype in both males and females (Supplemental Figure 1 ; supplemental material available online with this article; https://doi.org/10.1172/JCI124194DS1), but because it was more severe and difficult to propagate, we focused analysis on the R94Q-44 line.
Western blot using an antibody to Flag showed specific expression of transgenic MFN2
WT or MFN2 R94Q protein at the expected size of approximately 84 kDa ( Figure 1C) , with expression of the transgene slightly lower than that of endogenous mouse Mfn2 ( Figure 1C ). Immunofluorescence staining with anti-Flag antibody confirmed punctate cytoplasmic expression of exogenous MFN2
WT and MFN2 R94Q that colocalized with COXIV, consistent with mitochondrial localization in neurons in brain and spinal cord ( Figure 1D and Supplemental Figure 2) . Occasionally, the center of the densest mitochondrial clusters showed diminished COXIV staining, which may represent partial degradation of mitochondrial components at the center of the cluster (Supplemental Figure 2) . Of note, large accumulations of mitochondria were observed in neuronal cell bodies and proximal axons in cortex and spinal cord of Thy1.2-MFN2 R94Q mice; these were not present in Thy1. WT mice ( Figure 1D and Supplemental Figure 2 ). Similar mitochondrial clustering was also observed in the more severe R94Q-62 line (Supplemental Figure  1) . These mitochondrial accumulations were reminiscent of those previously observed in cultured (DRG) neurons expressing MFN2 and ventral horn (Supplemental Figure 4 , B and C, and Supplemental Figure 5A ). While no neuronal degeneration was observed, reactive astro-and microgliosis (enhanced Gfap and Iba1 immunoreactivity) were observed adjacent to projection neurons in cortical layer 5 and brain stem motor nuclei (Figure 2 , F and G, and Supplemental Figure 5 , B and C). Costaining with Flag to label mutant MFN2 R94Q -containing mitochondria showed that gliosis was most pronounced adjacent to neurons with cytoplasmic accumulations of mitochondria ( Figure 2F ). These results indicate that MFN2 R94Q expression produced widespread axon degeneration in the brain and spinal cord, particularly in regions containing long projection neurons. While neuronal cell bodies showed cytoplasmic mitochondrial accumulations and adjacent gliosis, no cell body loss was observed.
Mitochondrial clustering and morphology abnormalities induced by MFN2
R94Q
. To better visualize mitochondrial morphology and accumulations, we crossed MFN2 R94Q mice to transgenic mice with cyan fluorescent protein-labeled (CFP-labeled) mitochondria (39) . By 8 months, accumulations of CFP-labeled mitochondria were observed in hippocampus, cortex, thalamus, cerebellum, brain stem, and spinal cord in MFN2
:CFP-COX8A double-transgenic mice ( Figure  3A and Supplemental Figure 6A ); these were similar to what was seen with anti-Flag antibody ( Figure 1D ). Despite the accumulation of mitochondria in spinal motor neurons, mitochondria were present in distal axons and at neuromuscular junctions (NMJs), although they were frequently clumped or clustered ( Figure 3B ); this is reminiscent of findings seen in nerve biopsy samples from patients with CMT2A (40, 41) . While NMJs showed abnormal shape in the MFN-2
:CFP-COX8A double-transgenic mice, NMJ occupancy was normal at 8 months of age ( Figure 3B ). Neuronal cytoplasmic mitochondrial accumulations were positive for both p62 and ubiquitin ( Figure 3C and Supplemental Figure 6 , B-E), indicating they were marked for degradation by mitophagy. While early studies reported mitochondrial clustering from extremely high-level WT MFN2 overexpression in tissue culture (42) , no mitochondrial clustering was observed in MFN2 WT transgenic mice despite similar levels of expression, indicating this was a mutant-specific effect ( Figure 3C) .
Dominant negative disruption of mitochondrial fusion, but not mitophagy, by MFN2
R94Q
. Accumulations of fragmented mitochondria in cell bodies and axons from CMT2A-related MFN2 mutants were previously demonstrated in cultured neurons, together with disruption of mitochondrial fusion and transport induced by MFN2 R94Q (3, 26, 32) . However, given subsequent studies defining a role of MFN2 in mitophagy (5, 9), we investigated whether mutant MFN2 R94Q could disrupt mitophagy directly, leading to accumulation of mitochondria in the cell body that could not be degraded. Therefore, we examined mouse embryonic fibroblasts (MEFs) expressing MFN2
WT or MFN2 R94Q via lentiviruses. The mitochondrial aspect ratio (length/width), a measure of mitochondrial fusion (43) R94Q does not disrupt Parkin-mediated mitophagy and that the mitochondrial accumulations observed in MFN2 R94Q mice are not due to a direct block in mitochondrial degradation.
Conformation-altering peptides and MFN1 complementation for MFN2
R94Q -induced defects. The MFN2 R94Q mutation lies adjacent to the GTPase domain, which is a hot spot for CMT2A mutations (44) . While there are several models of MFN2 structure and conformation during mitochondrial fusion, all require GTPase function for fusion of the outer mitochondrial membrane (43, (45) (46) (47) (48) . In the most well-studied model, initial tethering involves C-terminal heptad-repeat 2 (HR2) domains in trans, with subsequent GTPase domain-mediated GTP hydrolysis (43, 45) . Therefore, MFN2 GTPase mutants such as MFN2 R94Q are competent for initial tethering with MFN1 or MFN2 on adjacent mitochondria, but are unable to complete fusion ( Figure 4A) .
To test this model and investigate potential therapeutic strategies for CMT2A, we first examined the effect of a recently described peptide (TAT-MP1 Gly ) that allosterically enhances mitochondrial fusion through altering C-terminal heptad repeat (HR1-HR2) interactions . In E, G, and I, data are represented as mean ± SEM. One-way ANOVA with Tukey's test. **P < 0.01; ****P < 0.0001. and promoting a "tethering permissive" state (43) . We observed that the TAT-MP1 Gly peptide partially rescued the fusion defect caused by MFN2 R94Q in MEFs lacking endogenous mouse Mfn2 (but retaining Mfn1), but could not rescue fusion in double-knockout MEFs (lacking both Mfn1 and Mfn2) ( Figure 4 , B and C). This supports that MFN2 R94Q by itself is fusion incompetent and that the TAT-MP1
Gly peptide requires at least one functioning Mfn isoform (in this case Mfn1) to promote fusion as well as that presumably in MEFs, the peptide is = 4) . In G-J, data are represented as mean ± SEM. Two-way ANOVA with Tukey's test was used for multiple comparison. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Figure 6G ). To define the pathways that drove this difference, we performed Gene Set Enrichment Analysis (GSEA) on the gene loadings ranked by the most positive to the most negative contributions to PC1 and found that oxidative phosphorylation and respiration electron transport were the pathways most significantly downregulated in PC1, indicating these drove the difference between the genotypes, and were rescued by MFN1 overexpression (Table 1) . Overall, these data provide strong evidence that the ratio of MFN1 to MFN2 is a key determinant of the sensitivity of the nervous system to the dominant negative effects of mutant MFN2 expression and support the idea that elevating MFN1 levels to restore the MFN1/MFN2 balance is a viable therapeutic strategy for CMT2A ( Figure 6H) .
Finally, to further characterize whether MFN2 R94Q functions as a dominant negative, we first examined whether MFN2
WT could also rescue the toxic effects of the mutant protein. As with MFN1 ( Figure  4D ), increased expression of MFN2 WT using lentivirus decreased the amount of mitochondrial aggregates induced by mutant MFN2 R94Q in SH-SY5Y cells in culture (Supplemental Figure 8A) WT double-transgenic mice showed restored weight gain (Supplemental Figure 8B) and that their behavior appeared overtly normal and indistinguishable from that of MFN2 R94Q :MFN1 mice. As in SH-SY5Y cells, hippocampal mitochondrial aggregation was rescued in the MFN2
R94Q :MFN2
WT doubletransgenic mice (Supplemental Figure 8C) . Finally, we observed that increasing MFN2
WT levels was able to rescue the axonal degeneration seen in the pyramidal tract of MFN2 R94Q mice (Supplemental Figure  8D) . These data strongly support that MFN2 R94Q mutant acts by a dominant negative mechanism that can be rescued by increasing the number of fusion-competent MFN1 or MFN2 molecules.
Discussion
In this study, we demonstrated that mice with transgenic expression of CMT2A-associated mutant MFN2 R94Q (but not WT) developed rescuing fusion by promoting Mfn1:Mfn1-mediated fusion events. Interestingly, lentiviral expression of MFN2 R94Q (but not MFN2 WT ) in SH-SY5Y neuroblastoma cells promoted mitochondrial clustering similar to that seen in the MFN2 R94Q mice, and clustering was exacerbated by the TAT-MP1
Gly peptide (Figure 4 , D and E). This suggests that, because of the lower levels of endogenous MFN1 in this neuronal cell line, the further promotion of an HR1-HR2 tethering permissive conformation of MFN2 R94Q enhanced the frequency of failed fusion events and mitochondrial clustering. In keeping with the idea that the MFN1/MFN2 ratio is the key determinant of sensitivity to the MFN2 R94Q mutant, the mitochondrial aggregation effect of MFN2 R94Q expression in SH-SY5Y cells was significantly rescued by increasing expression of MFN1 (Figure 4, D and E) .
In summary, these data support the idea that MFN2 R94Q is fusion incompetent and can suppress mitochondrial fusion in a dominant negative manner depending on the level of available fusion-competent MFN1 and MFN2 molecules in the cell. They further support the concept that the low levels of MFN1 in the nervous system potentially underlie the selective vulnerability of neurons in CMT2A (27) .
Phenotypic rescue of MFN2 R94Q mice by augmenting MFN1 expression in the nervous system. To examine whether altering the balance of MFN1 and MFN2 can mitigate the toxic effects of MFN2 R94Q , we generated mice expressing Flag-tagged human MFN1 under the mouse prion protein (PrP) promoter to drive expression in the nervous system ( Figure 5, A and B) . Western blot confirmed the expression of Flag-tagged MFN1 in both brain and spinal cord at levels slightly lower than Thy1.2-driven MFN2 R94Q ( Figure 5C ). As noted before, endogenous Mfn1 protein was nearly undetectable in the nervous system of nontransgenic animals ( Figure 5C) . Despite the high level of Flag-MFN1 expression over endogenous Mfn1, normal punctate mitochondrial staining was observed in cell bodies ( Figure 5D ) and animals were phenotypically and histologically normal throughout their life spans.
We then crossed Prp-MFN1 mice with Thy1.2-MFN2 R94Q mice to generate the double-transgenic (MFN2 :MFN1 doubletransgenic mice was restored to the level of nontransgenic mice ( Figure 5J ). In summary, increasing the level of MFN1 in the nervous system was well tolerated and provided complete or near-complete phenotypic rescue of defects in locomotor activity, sensorimotor coordination, and vision loss in MFN2 R94Q mice. Mitochondrial aggregation, axon degeneration, and transcriptomic signature rescued by MFN1 augmentation. We next determined whether increasing MFN1 levels in the nervous system could rescue the mitochondrial clustering, axon degeneration, and gliosis seen in Thy1. 2 less common features, including optic atrophy with vision loss, long tract spinal cord involvement, and brain involvement (15, 16, 18) . These data support clinical observations that CMT2A is a broader disease of the nervous system, with long peripheral and central a widespread axonopathy of the central and peripheral nervous systems, with defects in mitochondrial dynamics in neuronal cell bodies and axons. The phenotype resembled the severe early onset disease seen in most CMT2A patients and included some of the cord of MFN2 T105M transgenic mice (31) and neurons cultured from MFN2 T105M transgenic mice (28) . It has also been a consistent feature in tissue culture models (26, 27, 32) . Mitochondrial accumulations in cell bodies were labeled with p62, indicating they were marked for degradation via mitophagy (53); however, we did not see a difference in Parkin localization or recruitment of mitochondria to lysosomes in MEFs expressing MFN2 R94Q , suggesting that mitochondrial accumulations did not result from a mutantinduced block in mitophagy.
What are the causes and consequences of mitochondrial aggregation? Our data suggest that effects of mutant MFN2 R94Q on mitochondrial fusion (27, 32) and engagement with the transport apparatus (3, 26, 32) are likely to drive mitochondrial aggregation (see Figure 4A ). While there are several models of MFN2 structure and topology, all involve an initial tethering step, followed by GTP hydrolysis as a key step mediating membrane fusion (43, (45) (46) (47) (48) . The most well-studied of these models involves tethering via a C-terminal HR2 domain on adjacent mitochondria (43, 45, 54) . In this model, MFN exists either in a fusion-nonpermissive conformation through HR1-HR2 intramolecular binding or in fusion-permissive conformation through intermolecular HR2 binding. By this model, GTPase domain mutants (such as MFN2 R94Q ) are predicted to be competent for initial HR2-dependent tethering of adjacent mitochondria, but unable to mediate fusion because of GTPase dysfunction. Aggregates of unfused mitochondria would then result from tethered mitochondria that were unable to complete fusion or engage transport apparatus. This is supported by the observation that a peptide that allosterically modulates HR1-HR2 interactions led to increased MFN2-mediated mitochondrial clustering in a neuronal cell line ( Figure 4D ). However, it is important to note that alternative models exist whereby MFNs have a different membrane topology (47, 55) , and other models where initial tethering takes place via the GTPase domain rather than the C-terminal HR2 domain (46, 48) , so further structural biology studies are needed to reconcile these different models. Regardless of the precise molecular mechanism, mitochondrial aggregation accompanied by decreased mitochondrial fusion and axonal transport/localization likely drives axonal degeneration in Thy1.2-MFN2 R94Q -expressing mice, as numerous prior in vitro studies support that degeneration results from local axonal energy failure due to abnormal mitochondrial function, interaction with other organelles, including ER and lysosomes, and improper localization to sites of energy demand (2, 6, 26, 27, 52, 56) . Of note, a recent study showed that the MFN2 R94Q mutant in flies led to similar cytoplasmic aggregates of unfused mitochondria and axonal pathology, supporting the dominant negative tethering model for the action of this and other GTPase domain mutants (57) . Interestingly, the authors found that 2 other mutants (L76P and R364W) showed evidence of enhanced fusion, but surprisingly, still caused mitochondrial dysfunction and altered axonal mitochondrial localization. This was consistent with earlier findings that the L76P mutant disrupted mitochondrial transport (32, 58), but not fusion (27) . Further work will need to be done to determine whether MFN1 augmentation will mitigate the toxic effects of other dominant MFN2 mutants that may have different mechanisms of action.
In addition to modeling the toxic effects of mutant MFN2 that lead to CMT2A, we provided what we believe is the first in vivo proof of concept that restoring MFN1:MFN2 balance by augmenting axons most sensitive to the effects of mutant MFN2 (18, 34, (49) (50) (51) . Several previous mouse models of CMT2A from mutant MFN2 have been generated, but none with the diffuse axonopathy seen in Thy1. R94Q mice, particularly in the central nervous system.
HB9-Mfn2
T105M transgenic mice developed hind limb defects, but this was distinct from human phenotypes in that it was only seen in homozygotes and was congenital and nonprogressive, likely because of promoter inactivation after development (28) . Mice expressing MFN2
R94Q under the neuron-specific enolase (NSE) promoter showed motor deficits starting at 5 months of age (29, 52) , and mice with MFN2 T105M expressed inducibly in the nervous system under the Rosa locus developed only mild gait defects (31) . Finally, MFN2 mutant knockin mice either had no reported phenotype (27) or mild late-onset deficits (30) . These differences are likely due to the use of different promoters and the requirement for at least mild overexpression to promote a phenotype. It is notable that, while we observed axonal degeneration in the brain and spinal cord of Thy1.2-MFN2 R94Q mice, we observed axonal atrophy in the distal peripheral nerve without axon loss at a time when the animals manifested a profound behavioral phenotype. Axonal atrophy without degeneration has been observed in a prior CMT2A model (29) as well as other mouse models of axonal CMT (37, 38) . These data suggest that a critical threshold of mutant MFN2 expression is required to produce peripheral axonal degeneration in mice, which may be due to species-specific factors, such as shorter axon length or uncharacterized genetic modifiers. Likewise, they suggest that the profound behavioral phenotype in Thy1. 2 
-MFN2
R94Q mice is presumably driven by a combination of vision loss and sensory-motor axonal damage in brain and spinal cord. While transgene insertion into the Y chromosome was a drawback of the R94Q-44 line, as female mice could not be studied, clinical data from humans do not support a sex difference in phenotypes, and while the R94Q-62 line was too severe to maintain, it showed similar pathology in both males and females.
The most striking pathologic feature in Thy1.2-MFN2 R94Q mice was mitochondrial clustering and aggregation in neuronal cell bodies and proximal and distal axons. Similar abnormal mitochondrial size, morphology, and clustering has been reported in the nerve biopsies from CMT2A patients (40, 41). Mutant-specific mitochondrial aggregation was also observed in brain and spinal ). An AgeI-Kosak-ATG-FLAG sequence was inserted after the 5′ UTR, and an XhoI site was inserted before the 3′ UTR of human MFN1 cDNA using QuikChange. Flag-MFN1 was then cut out from the pBluescriptR plasmid with AgeI and XhoI restriction sites and subcloned into the PrP promoter construct. The final PrP-Flag-MFN1 plasmid was linearized with NotI restriction enzyme digestion. The linearized plasmid was used for pronuclear injection to create transgenic mice on the C57BL/6J background. Genotyping of founder mice was done using PCR. Primers were as follows: forward, 5′-CAATTCTAGTTTTCTCTTTTTGTTGTTTTAAAGGACTCC; reverse, 5′-GGGAGAACTTTATCCCACAACA. 
Mouse behavioral analysis
Rotarod test. The rotarod was used to measure motor function and coordination. Mice were placed on a rod elevated 18 inches above a soft surface. For each rotarod session, the rod was set at a constant speed of 5 rpm with a cut-off time at 4 minutes. Each session consisted of 3 trials with a 30-minute intertrial period in which mice were placed back in their home cages. The latency for the mice to fall off the rod was averaged across the 3 trials. Grip-strength test. This test measures grip-force ability of the forelimbs and hind limbs. For measuring tensile force, the mouse was held by the base of the tail and allowed to grip a metal grid either with its forepaws alone or with both forepaws and hind paws. The mouse was then gently pulled horizontally to exert the tensile force. The peak force (in g) at the point the mouse released its grip was recorded through a digital force gauge attached to the metal grid. Three successive measurements were averaged for both the forelimbs and the 4-paws grip strengths.
Open-field test. Spontaneous motor activity of the mice was measured in the open-field test. Mice were individually placed into a clear Plexiglas chamber (16 inches long × 16 inches wide × 15 inches high) surrounded by 2 bands of photobeams and optical sensors that mealevels of MFN1 in the nervous system is a viable therapeutic approach for CMT2A, as Thy1. :Prp-MFN1 doubletransgenic animals showed near complete rescue of ocular, neuromuscular, and histologic phenotypes seen in Thy1. mice. While Mfn1-or Mfn2-null mice are embryonic lethal due to placental defects (1), conditional removal of Mfn2, but not Mfn1, postnatally led specifically to neurodegeneration (10, 23, 24) , likely due to the fact that Mfn1 levels are very low in the nervous system (27) . MFN1 and MFN2 are 80% identical (22) and are capable of heterodimer formation (1) , and MFN1 expression can rescue mitochondrial fusion and transport defects caused by the loss of MFN2 in MEFs and DRG neurons (26, 27) , but not other functions, such as altered ER-mitochondrial interactions (2) . Therefore, these data support the concepts that (a) the origin of nervous system-specific defects in CMT2A is due to the relative lack of MFN1 expression and (b) functions that are MFN2 specific are not critical for the toxicity of MFN2 mutants in CMT2A, as they would presumably not be rescued by restoring MFN1:MFN2 balance.
We also observed that increasing MFN2 levels in neurons (in SH-SY5Y cells or by generating double-transgenic MFN2
R94Q
:MFN2 WT mice) could similarly rescue the dominant negative effect of mutant MFN2
. This further supports the idea that the relative number of functional MFN molecules (either MFN1 or MFN2) in a tissue is the key driver of toxicity of mutant MFN2 R94Q and that increasing either MFN1 or MFN2 could be used therapeutically in CMT2A. However, for approaches increasing endogenous gene expression, augmenting MFN1 would be preferable, as it would effectively change the ratio of functional MFN molecules, while augmenting MFN2 expression would have no effect on this ratio or could worsen the phenotype.
It is unknown why MFN1 levels are very low in the adult nervous system, but the fact that Prp-MFN1 transgenic mice are phenotypically normal indicates that MFN1 overexpression at levels equivalent to MFN2 is well tolerated. Likewise, increased levels of MFN2 in the Thy1. WT mice were also well tolerated and could similarly rescue the toxic effects of mutant MFN2 expression. This raises the possibility that augmenting MFN1 or MFN2 expression in the nervous system may have broader therapeutic applications beyond CMT2A. Impaired mitochondrial dynamics, including fusion, fission, and transport, have been implicated in other forms of CMT (59) (60) (61) (62) and many other neurodegenerative diseases, including Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Alzheimer's disease (7, 8, 63) . Indeed, a recent report indicated that increasing MFN2 levels in neurons was protective in a model of amyotrophic lateral sclerosis, suggesting that MFN2 WT mice may be intrinsically more resistant to neurodegeneration (64) . Although upstream mechanisms vary across these neurodegenerative diseases, augmenting MFN1 or MFN2 could mitigate mitochondrial dysfunction that occurs as a shared pathophysiology in neurodegeneration. Immunohistochemistry analysis of retinal whole mount and retinal sections. Retinal whole mount was prepared according to published protocols (67) . Briefly, eyeballs were fixed in 4% PFA for 1 hour and transferred to PBS (pH 7.35-7.45) for dissecting. Under the dissecting microscope, the cornea and lens were removed and 4 equal cuts were made to flatten the eyeball. Neural retina was dissected out, transferred to filter paper, and fixed for 1 hour in the same fixative. The neural retina was washed with PBS, infiltrated with gradient sucrose (10%, 20%, and 30%), and left in 30% sucrose overnight at 4°C. On the next day, the retina was frozen and thawed 3 times in an Eppendorf tube with 30% sucrose on dry ice. The retina was washed with PBS and processed for immunofluorescence staining. Retinal sections were prepared according to published protocols (67) . Briefly, eyes were removed and immersed in 2% PFA for 1 hour. Eyes were then infiltrated with sucrose and embedded in OCT. Horizontal frozen sections (12 μm) were cut on a cryostat. The primary antibodies used were anti-neurofilament (RT97, 1:1,000, catalog CBL212, MilliporeSigma) and anti-Brn3a (1:200, catalog sc-31984, Santa Cruz Biotechnology Inc.) for RGCs.
Methods
Generation of transgenic mice
Retinas were examined, and images were taken using the Leica DM6000B microscope (Leica Microsystems). The numbers of RGC cells (Brn3a positive) in the retinal whole mount were quantified. Four images in the center and in the periphery were taken, respectively, per animal. Four or five animals were used per genotype. The quantification was performed using ImageJ software with the threshold and the analyze particles functions.
NMJ staining. Quadriceps muscle was dissected from mice and post-fixed with 4% PFA on ice for 1 hour. After PBS wash, muscle was embedded with 4% low melting agarose. Serial sections (70 μm thick) were cut. Agarose sections were placed in a 24-well plate, blocked with 5% normal donkey serum (diluted in PBS) for 30 minutes, and stained with 0.5 μg/ml α-bungarotoxin (catalog B-13423, Thermo Fisher Scientific) for 1 hour. The stained sections were mounted on slides with ProLong Gold Antifade Mountant. Z-stack images were taken using a Nikon Eclipse Ti microscope.
Fluoro-Jade staining of degenerating axons. Sets of paraffin sections (4 μm) were deparaffinized using xylene and then hydrated with decreasing concentrations of ethanol. The slides were immersed in the following solutions in sequence: PBS, 5 minutes; 1%NaOH in 80% ethanol, 5 minutes; 70% ethanol, 2 minutes; H 2 O, 2 minutes; 0.06% KMnO4 in H 2 O, 17 minutes; H 2 O, 2 minutes; 0.001% Fluoro-Jade C (catalog AG235, MilliporeSigma) in 0.1% acetic acid with DAPI, 30 minutes; and H 2 O, 3 times, 2 minutes per time. Then slides were dried by draining excess water and placed on a slide warmer at 50°C for 10 minutes. Finally, slides were coverslipped using DPX mounting medium. Images were taken using an Olympus BX51 Upright Microscope. Fluoro-Jade signals were quantified with ImageJ software. After background subtraction, Fluoro-Jade-positive signals per ROI were quantified and presented as pixle 2 /mm 2 ROI.
Toluidine blue staining of spinal cord and tibial nerve plastic sections. A 1 ml long segment of spinal cord (between thoracic and lumbar region) or distal tibial nerve were harvested for processing of epoxy resin blocks. The specimens were fixed in 3% glutaraldehyde in 0.1M phosphate buffer, osmicated in 2% osmium tetroxide in 0.1M phosphate buffer, dehydrated in increasing graded solutions of ethanol and acetone, and finally embedded in epoxy resin. Sections (0.5 μm) were cut and stained with toluidine blue. Axon counts and axon area sured horizontal locomotor and vertical rearing activity. Animals moved freely within the enclosure for 60 minutes. Movement was detected as breaks within the photobeam matrices and automatically recorded using PAS software (San Diego Instruments).
Visual acuity test. Visual acuity measured by OKR was conducted on both mutated and control mice. The test was done in an observerblinded fashion as reported previously (66) .
Western blot analysis. Mouse brain or spinal cord tissue was lysed with RIPA buffer and quantified using BCA protein assay (Pierce). Protein samples were separated on 10% precast polyacrylamide gels and transferred to nitrocellulose blots. Primary antibodies for Western blot included anti-Flag (MilliporeSigma, catalog F3165), anti-MFN2 (Abcam, catalog ab56889), anti-MFN1 (Proteintech, catalog 13798-1-AP), and anti-GAPDH (MilliporeSigma, catalog G8795). Signals were detected using fluorescent secondary antibodies and the Odyssey imager from LI-COR.
Immunohistochemistry analysis of brain, spinal cord, and optic nerve. Tissue were fixed in 4% paraformaldehyde (PFA) (pH 7.4) for 5 days for brain and spinal cord and for 2 days for optic nerve. After fixation, tissues were embedded in paraffin and 4 μm thick serial sections were cut, including coronal sections for brain, cross sections for spinal cord, and both cross and longitudinal sections for optic nerve. Sets of sections were deparaffinized using xylene and then hydrated with decreasing concentrations of ethanol. After deparaffinization, antigen retrieval was performed by submerging the sections in citrate buffer (pH 6.0) and microwaving at 800W for 10 minutes. For SMI32 staining, the microwave step was followed by 5 minutes incubation in 90% formic acid. For immunostaining, the sections were treated with 1% H 2 O 2 /methanol and blocked with 10% horse serum, followed by overnight incubation with primary antibodies. The next day, sections were incubated with fluorescent secondary antibodies for 4 hours at room temperature. Nuclei were stained with DAPI and mounted with ProLong Gold Antifade Mountant (Thermo Fisher Scientific). Positive and negative controls were run along each batch of sections processed.
Primary antibodies were as follows: anti-FLAG (1:500, catalog F3165, Sigma-Aldrich), anti-COXIV (1:200, catalog ab16056, Abcam Inc.), anti-p62 (1:500, catalog BML-PW9860-0100, Enzo Life Sciences), anti-ubiquitin (1:500, catalog MAB1510, MilliporeSigma), anti-neurofilament H nonphosphorylated (SMI 32, 1:500, catalog 801701, Biolegend), anti-NeuN 
